赵攀，副主任医师，副教授，硕士研究生导师，受聘为中华医学会、中华中医药学会、中国研究型医院学会等国家级学会专科分会委员，第一作者或通讯作者在Journal of Hepatology（IF 20.586）, Critical Care Medicine（IF 6.312）等著名期刊发表SCI论文32篇，共同第一作者SCI论文1篇，部分论文入选ESI高被引论文。

赵攀博士主要研究领域为疑难肝病的基础与临床诊治，对慢性乙型肝炎、急性肝衰竭有系统性研究：开展了免疫耐受期慢性乙型肝炎儿童抗病毒治疗的随机对照临床试验以及婴儿期发病的乙型肝炎患儿抗病毒治疗的前瞻性队列研究，相关论文均以原始论著形式刊登于肝脏病领域顶级期刊Journal of Hepatology；这两项研究均为国际首次报道，为国内外儿童乙型肝炎病毒感染临床管理指南的完善和发展做出了重要贡献；在急性肝衰竭方面，赵攀博士组建了急性肝衰竭研究团队（Acute Liver Failure Study Team），国际上首次报道了中国多中心急性肝衰竭流行病学研究结果，发表在医学权威期刊Critical Care Medicine上的关于中草药急性肝衰竭的论文被该期刊给予同期述评，急性肝衰竭的系列文章在国内外产生广泛影响并被EASL等国际指南参考引用。

发表论文列出如下（*通讯作者）。

[1] Zhu S, Zhang H, Dong Y, Wang L, Xu Z, Liu W, Gan Y, Tang H, Chen D, Wang F, Zhao P*. Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study. J Hepatol, 2018;68(6):1123-1128.

[2] Zhao P*, Wang C, Liu W, Wang F. Acute liver failure associated with traditional chinese medicine: report of 30 cases from seven tertiary hospitals in China. Crit Care Med, 2014; 42(4):e296-e299.

[3] Zhao P*, Wang C, Huang L, Xu D, Li T. Comparison of rescue strategies in lamivudine-resistant patients with chronic hepatitis B. Antiviral Res, 2012; 96(2):100-104.

[4] Zhao P*, Wang C, Liu W, et al. Causes and outcomes of acute liver failure in China. PLoS One, 2013; 8(11):e80991.

[5] Gao X, Zhao P, Hu J, et al. MicroRNA-194 protects against chronic hepatitis B-related liver damage by promoting hepatocyte growth via ACVR2B. J Cell Mol Med, 2018;22(9):4534-4544. (Co-first Author)

[6] Zhao P*, Wang C, Liu W, et al. Acute liver failure in Chinese children: a multicenter investigation. Hepatobiliary Pancreat Dis Int, 2014; 13(3):276-280.

[7] Zhao P, Wei Z, Liu W. Is there a straightforward relationship between hepatitis C virus infection and diabetes? Hepatology, 2015; 61(3):1097-1098.

[8] Zhao P, Wei Z, Han J. Adverse effects of proton pump inhibitors in chronic kidney disease. JAMA Intern Med, 2016;176(6):867.

[9] Zhao P*, Liu W, Zhao J, et al. Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naive Asian patients with chronic hepatitis B: a meta-analysis. Virol J, 2011; 8:75.

[10] Zhao P*, Wang C, Liu W. Can Experience from adults regarding acute liver failure fit children? Indian J Pediatr, 2014; 81(5):501-503.

[11] Wang C, Zhao P*, Liu W. Acute liver failure caused by severe acute hepatitis B: a case series from a multi-center investigation. Ann Clin Microbiol Antimicrob, 2014; 13(1):23.

[12] Zhao P, Han Y. Low incidence of positive smooth muscle antibody and high incidence of isolated IgM elevation in Chinese patients with autoimmune hepatitis and primary biliary cirrhosis overlap syndrome: a retrospective study. BMC Gastroenterol, 2012; 12:1.

[13] Zhao P, Yang HZ, Li JF, et al. A case of autoimmune hepatitis and primary biliary cirrhosis overlap syndrome treated with Chinese herbs. Chin J Integr Med, 2013; 19(6):468-470.

[14] Zhao P*, Wang C, Yang H, et al. Outcomes of rescue therapy in patients with autoimmune hepatitis and primary biliary cirrhosis overlap syndrome after failing response to ursodeoxycholic acid monotherapy: A case series study. HealthMed, 2013; 7(6):1998-2003.

[15] Zhao P, Liu WW, Li JF, et al. Predictors of liver failure in primary biliary cirrhosis. Ups J Med Sci, 2015; 120(1):47-51.

[16] Zhao P, Yang HZ, Lv HY, et al. Efficacy of lianhuaqingwen capsule compared with oseltamivir for influenza A virus infection: a meta-analysis of randomized, controlled trials. Altern Ther Health Med, 2014; 20(2):25-30.

[17] Wang C, Zhao P*, Liu W. Risk of incident coronary artery disease in patients with primary biliary cirrhosis. Int J Clin Exp Med, 2014; 7(9):2921-2924.

[18] Wang C, Zhao P*, Luo P, et al. Prevalence and risk factors of coronary artery disease in patients with chronic viral hepatitis. Postgrad Med, 2015;127(8):786-790. 

[19] Wei S, Niu M, Wang J, Wang J, Su H, Luo S, Zhang X, Guo Y, Liu L, Liu F, Zhao Q, Chen H, Xiao X, Zhao P*, Zhao Y. A network pharmacology approach to discover active compounds and action mechanisms of San-Cao Granule for treatment of liver fibrosis. Drug Des Devel Ther, 2016; 10:733-743.

[20] Tang H, Zhao P*, Chen J, Liu L. Congenital pemphigus syphiliticus. Int J Infect Dis, 2016;49:149-150.

[21] Li Y, Xia H, Wu M, Wang J, Lu X, Wei S, Li K, Wang L, Wang R, Zhao P, Zhao Y, Xiao X. Evaluation of the antibacterial effects of flavonoid combination from the leaves of Dracontomelon dao by microcalorimetry and the quadratic rotary combination design. Front Pharmacol, 2017;8:70.

[22] Zhao P*, Zhao Y, Wei Z, Chen J, Yan L. Wernicke encephalopathy in a patient with liver failure: Clinical case report. Medicine (Baltimore), 2016;95(27):e3651.

[23] Li X, Liu Y, Zhao P, Wang Y, Chen L, Xin S, Zhang XX, Xu D. Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection. Antivir Ther, 2015;20(2):141-147.

[24] Huang A, Hao S, Zhang L, Li B, Sun Y, Chang B, Teng G, Zhang W, Liang Q, Tian H, Shang L, Zhao P*, Zou Z. Clinical characteristics and prognosis of severe alcoholic hepatitis in a cohort of 258 Chinese patients. Int J Clin Exp Med, 2017;10(4):7006-7010.

[25] Zhao P*, Liu B, Wang C; Acute Liver Failure Study Team (ALFST). Hepatotoxicity evaluation of traditional Chinese medicines using a computational molecular model. Clin Toxicol (Phila), 2017;55(9):996-1000.

[26] Zhu S, Dong Y, Wang L, Liu W, Zhao P*. Early initiation of antiviral therapy contributes to a rapid and significant loss of serum HBsAg in infantile-onset hepatitis B. Journal of Hepatology, 2019;71(5):871-875.

[27] Wang C, Gao H, Sun J, Wang L, Li W, Zu X, Cheng P, Wei S, Zhao P*. Cardiac involvement in Wilson’s disease: a retrospective cohort study. European Journal of Gastroenterology and Hepatology, 2022;34(11):1147-1150.

[28] Wang L, Liu S, Wang C, Zhu M, Guo Y, Zhao P*. Hepatocyte proliferation favours viral clearance in young children with chronic hepatitis B virus infection. Acta Paediatrica, 2023;112(2):305-310.

[29] Qi J, Liu H, Wang L, Chen Y, Fu J, Zheng H, Wang C, Chen J, Wang R, Zhao P*. Follow-up of newborns with hepatitis B antigenemia. Infectious Diseases and Therapy, 2022;11(6):2233-2240.

[30] Sun J, Dong Z, Chang Z, Liu H, Jiang Q, Zhang D, Lu S, Jia X, Wu D, Ge A, Zhao P*, Wang J, Lu Y. MARCH6 promotes hepatocellular carcinoma development through up-regulation of ATF2. BMC Cancer, 2021;21(1):827.

[31] Dong Y, Li M, Zhu S, Gao X, Zhao P*. De novo combination antiviral therapy in e antigen-negative chronic hepatitis B virus-infected paediatric patients with advanced fibrosis. J Viral Hepat, 2020;27(12):1338-1343.

[32] Dong Y, Li A, Zhu S, Chen W, Li M, Zhao P*. Biopsy-proven liver cirrhosis in young children: A 10-year cohort study. J Viral Hepat, 2021;28(6):959-963.

[33] Zhao P*, Lu Y, Wang C, Wang L, Li J, Li M. Clinical, pathological and genetic characteristics of pediatric hepatocellular carcinoma associated with hepatitis B virus infection. J Hepatocell Carcinoma, 2021;8:361-367.